12.16.14
IMRIS Inc. has received Health Canada licensing to incorporate next-generation magnetic resonance imaging (MRI) core technology into the Visius Surgical Theatre for sales and marketing in the country.
The newest imaging technology, based on the Siemens Aera 1.5T (Tesla) and Skyra 3.0T MRI scanners, helps IMRIS deliver better image quality, faster 3-D image acquisition, and improved ease-of-use and workflow during surgical procedures using intraoperative MRI (iMRI), the company claims. IMRIS received U.S. Food and Drug Administration clearance for the advancements in February 2014 and CE mark authorization in Europe in July 2014.
“Hospitals who adopt this technology in our Visius solution will have access to the highest quality MR applications and images within the operating room setting,” said IMRIS President/CEO Jay
D. Miller. “This latest imaging technology in the hands of neurosurgeons is improving patient outcomes and making newer minimally-invasive treatment options for brain tumors, epilepsy and other therapies work better.”
Inside a Visius Surgical Theatre equipped with high-field iMRI, surgeons have on-demand access to real-time data and imaging during the procedure as the scanner moves on ceiling-mounted rails.
IMRIS develops image-guided therapy solutions through its Visius Surgical Theatre, a multifunctional surgical environment that provides intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. The multi-room suites incorporate diagnostic quality high-field MR, CT and angiomodalities accessed in the operating room setting. Visius Surgical Theatres serve the neurosurgical, spinal, cardiovascular and cerebrovascular markets. The company is based in Winnipeg, Manitoba, Canada, and has offices in the United States, China, Japan, Europe and Australia.